AstraZeneca Ends Seroquel Case Against Biovail

Law360, New York (May 2, 2011, 7:06 PM EDT) -- A New Jersey federal judge on Monday signed off on a joint stipulation of dismissal of AstraZeneca Pharmaceuticals LP’s case alleging Biovail Corp. infringed its patents by seeking to launch a generic version of AstraZeneca’s popular treatment for bipolar disorder and schizophrenia, Seroquel XR.

AstraZeneca and Biovail on Friday asked for the case to be dismissed after Biovail made a regulatory filing pursuant to which it agreed not to commercially sell its purportedly generic drug until after the expiration of the two patents-in-suit.

Following the action’s...
To view the full article, register now.